Stephan N Wagner

List of Publications by Year
in descending order

74 papers	13,578 citations	125106 35 h-index	84171 75 g-index
79 all docs	79 docs citations	79 times ranked	22164 citing authors

#	Article	IF	Citations
1	Anaphylactic reaction to carboplatin diagnosed by skin testingâ€”aÂreliable tool in platinum-based immediate-type hypersensitivity reactions. Wiener Medizinische Wochenschrift, 2023, 173, 256-259.	0.5	2
2	Spatiotemporal Analysis of B Cell- and Antibody Secreting Cell-Subsets in Human Melanoma Reveals Metastasis-, Tumor Stage-, and Age-Associated Dynamics. Frontiers in Cell and Developmental Biology, 2021, 9, 677944.	1.8	3
3	A Standardized Analysis of Tertiary Lymphoid Structures in Human Melanoma: Disease Progression- and Tumor Site-Associated Changes With Germinal Center Alteration. Frontiers in Immunology, 2021, 12, 675146.	2.2	31
4	Loss of Lymphotoxin Alpha-Expressing Memory B Cells Correlates with Metastasis of Human Primary Melanoma. Diagnostics, 2021, 11, 1238.	1.3	6
5	B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nature Communications, 2019, 10, 4186.	5.8	236
6	Digital image analysis improves precision of <scp>PD</scp>â€L1 scoring in cutaneous melanoma. Histopathology, 2018, 73, 397-406.	1.6	54
7	A slow-cycling subpopulation of melanoma cells with highly invasive properties. Oncogene, 2018, 37, 302-312.	2.6	65
8	Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nature Communications, 2017, 8, 607.	5.8	109
9	Dual c-JunN-terminal kinase-cyclin D1 and extracellular signal-related kinase-c-Jun disjunction in human melanoma. British Journal of Dermatology, 2016, 175, 1221-1231.	1.4	15
10	Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome. Human Pathology, 2016, 54, 157-164.	1.1	81
11	Signal Sequence Receptor 2 is required for survival of human melanoma cells as part of an unfolded protein response to endoplasmic reticulum stress. Mutagenesis, 2016, 31, 573-582.	1.0	14
12	The role of tumor microenvironment in melanoma therapy resistance. Melanoma Management, 2016, 3, 23-32.	0.1	18
13	RanBP3 Regulates Melanoma Cell Proliferation via Selective Control of Nuclear Export. Journal of Investigative Dermatology, 2016, 136, 264-274.	0.3	6
14	A Peptide to Reduce Pulmonary Edema in a Rat Model of Lung Transplantation. PLoS ONE, 2015, 10, e0142115.	1.1	8
15	Comprehensive Comparative and Semiquantitative Proteome of a Very Low Number of Native and Matched Epsteinâ€“Barr-Virus-Transformed B Lymphocytes Infiltrating Human Melanoma. Journal of Proteome Research, 2014, 13, 2830-2845.	1.8	15
16	MTSS1 is a metastasis driver in a subset of human melanomas. Nature Communications, 2014, 5, 3465.	5.8	52
17	A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF. Oncogene, 2014, 33, 2531-2539.	2.6	29
18	Suppression of Nucleotide Metabolism Underlies the Establishment and Maintenance of Oncogene-Induced Senescence. Cell Reports, 2013, 3, 1252-1265.	2.9	228

#	Article	IF	Citations
19	Combining Filter-Aided Sample Preparation and Pseudoshotgun Technology To Profile the Proteome of a Low Number of Early Passage Human Melanoma Cells. Journal of Proteome Research, 2013, 12, 1040-1048.	1.8	33
20	NVP-LDE225, a Potent and Selective SMOOTHENED Antagonist Reduces Melanoma Growth In Vitro and In Vivo. PLoS ONE, 2013, 8, e69064.	1.1	42
21	Î³Î´ T-cell Lymphoma Mimicking SÃ©zary Syndrome. Acta Dermato-Venereologica, 2012, 92, 166-168.	0.6	2
22	Dual Suppression of the Cyclin-Dependent Kinase Inhibitors CDKN2C and CDKN1A in Human Melanoma. Journal of the National Cancer Institute, 2012, 104, 1673-1679.	3.0	35
23	Targeting CD20 in Melanoma Patients at High Risk of Disease Recurrence. Molecular Therapy, 2012, 20, 1056-1062.	3.7	69
24	Immunotargeting of tumor subpopulations in melanoma patients. OncoImmunology, 2012, 1, 1454-1456.	2.1	6
25	Inhibition of CRM1-Mediated Nucleocytoplasmic Transport: Triggering Human Melanoma Cell Apoptosis by Perturbing Multiple Cellular Pathways. Journal of Investigative Dermatology, 2012, 132, 2780-2790.	0.3	43
26	Melanoma genome sequencing reveals frequent PREX2 mutations. Nature, 2012, 485, 502-506.	13.7	671
27	A Landscape of Driver Mutations in Melanoma. Cell, 2012, 150, 251-263.	13.5	2,247
28	An Attempt at a Molecular Prediction of Metastasis in Patients with Primary Cutaneous Melanoma. PLoS ONE, 2012, 7, e49865.	1.1	13
29	Polo-Like Kinase 1 Is a Potential Therapeutic Target in Human Melanoma. Journal of Investigative Dermatology, 2011, 131, 1886-1895.	0.3	23
30	Integrative Genome Comparison of Primary and Metastatic Melanomas. PLoS ONE, 2010, 5, e10770.	1.1	166
31	Induction of Targeted Cell Migration by Cutaneous Administration of a DNA Vector Encoding a Biologically Active Chemokine CCL21. Journal of Investigative Dermatology, 2010, 130, 1611-1623.	0.3	4
32	Combination of an EGFR blocker and a COXâ€2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. JDDG - Journal of the German Society of Dermatology, 2008, 6, 1066-1069.	0.4	46
33	Kombination eines EGFR-Blockers mit einem COX-2-Inhibitor fÃ¼r die Behandlung des fortgeschrittenen kutanen Plattenepithelkarzinoms. JDDG - Journal of the German Society of Dermatology, 2008, 6, no.	0.4	0
34	Gene Expression Changes in an Animal Melanoma Model Correlate with Aggressiveness of Human Melanoma Metastases. Molecular Cancer Research, 2008, 6, 760-769.	1.5	216
35	Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group. Melanoma Research, 2008, 18, 353-358.	0.6	24
36	Growth Factors and Oncogenes as Targets in Melanoma: Lost inÂTranslation?. Advances in Dermatology, 2007, 23, 99-129.	2.0	16

#	Article	IF	Citations
37	High-throughput oncogene mutation profiling in human cancer. Nature Genetics, 2007, 39, 347-351.	9.4	927
38	HLA-G expression in malignant melanoma. Seminars in Cancer Biology, 2007, 17, 422-429.	4.3	36
39	Phase II Trial of a Toll-Like Receptor 9â€“Activating Oligonucleotide in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2006, 24, 5716-5724.	0.8	197
40	Comparative Oncogenomics Identifies NEDD9 as a Melanoma Metastasis Gene. Cell, 2006, 125, 1269-1281.	13.5	380
41	Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature, 2005, 436, 117-122.	13.7	1,329
42	A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunology, Immunotherapy, 2005, 54, 453-467.	2.0	61
43	EMPACT syndrome. EMPACT-Syndrom. JDDG - Journal of the German Society of Dermatology, 2005, 3, 39-43.	0.4	17
44	CpG Motifs Are Efficient Adjuvants for DNA Cancer Vaccines. Journal of Investigative Dermatology, 2004, 123, 371-379.	0.3	55
45	Alterations of Î”TA-p 73 splice transcripts during melanoma development and progression. International Journal of Cancer, 2004, 108, 162-166.	2.3	50
46	Differential downregulation of endoplasmic reticulum-residing chaperones calnexin and calreticulin in human metastatic melanoma. Cancer Letters, 2004, 203, 225-231.	3.2	36
47	Downregulation of tapasin expression in progressive human malignant melanoma. Archives of Dermatological Research, 2003, 295, 43-49.	1.1	76
48	CD44 variant isoform v10 is expressed on tumor-infiltrating lymphocytes and mediates hyaluronan-independent heterotypic cell-cell adhesion to melanoma cells. Experimental Dermatology, 2003, 12, 204-212.	1.4	9
49	Activated Neutrophils Exert Antitumor Activity Against Human Melanoma Cells: Reactive Oxygen Species-Induced Mechanisms and Their Modulation by Granulocyte-Macrophageâ€“Colony-Stimulating Factor. Journal of Investigative Dermatology, 2003, 121, 936-938.	0.3	40
50	Expression of Classic and Nonclassic HLA Class I Antigens in Uveal Melanoma. , 2003, 44, 2016.		24
51	Association of TAP1 downregulation in human primary melanoma lesions with lack of spontaneous regression. Melanoma Research, 2003, 13, 253-258.	0.6	29
52	Immunoproteasome subunits LMP2 and LMP7 downregulation in primary malignant melanoma lesions. Melanoma Research, 2003, 13, 371-377.	0.6	30
53	Venous Leg Ulcers in a Patient with Klinefelter's Syndrome and Increased Activity of Plasminogen Activator Inhibitor-1. Acta Dermato-Venereologica, 2003, 83, 149-150.	0.6	6
54	Induction of Specific Immune Responses by Polycation-Based Vaccines. Journal of Immunology, 2002, 169, 5217-5226.	0.4	29

#	Article	IF	Citations
55	Unbalanced overexpression of the mutant allele in murine Patched mutants. Carcinogenesis, 2002, 23, 727-734.	1.3	40
56	Treatment of disseminated ocular melanoma with sequential fotemustine, interferon Î±, and interleukin 2. British Journal of Cancer, 2002, 87, 840-845.	2.9	127
57	Epithelioid Sarcoma: A Frequently Misdiagnosed Neoplasm. Acta Dermato-Venereologica, 2001, 81, 139-140.	0.6	2
58	Hyaluronan-Independent Adhesion of CD44H+ and CD44v10+ Lymphocytes to Dermal Microvascular Endothelial Cells and Keratinocytes. Journal of Investigative Dermatology, 2001, 117, 949-957.	0.3	11
59	Involvement of chemokine receptors in breast cancer metastasis. Nature, 2001, 410, 50-56.	13.7	4,837
60	Intracutaneous Genetic Immunization with Autologous Melanoma-Associated Antigen Pmel17/gp100 Induces T Cell-Mediated Tumor Protection In Vivo. Journal of Investigative Dermatology, 2000, 115, 1082-1087.	0.3	16
61	Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma. Lancet, The, 2000, 356, 220-221.	6.3	101
62	Predominant Expression of CD44 Splice Variant v10 in Malignant and Reactive Human Skin Lymphocytes. Journal of Investigative Dermatology, 1998, 111, 464-471.	0.3	21
63	Homozygous deletion of the p16INK4a and the p15INK4b tumour suppressor genes in a subset of human sporadic cutaneous malignant melanoma. British Journal of Dermatology, 1998, 138, 13-21.	1.4	44
64	Analysis of Pmel17/gp100 expression in primary human tissue specimens: implications for melanoma immuno- and gene-therapy. Cancer Immunology, Immunotherapy, 1997, 44, 239-247.	2.0	41
65	Sites of urokinase-type plasminogen activator expression and distribution of its receptor in the normal human kidney. Histochemistry and Cell Biology, 1996, 105, 53-60.	0.8	53
66	Lithium and psoriasis: cytokine modulation of cultured lymphocytes and psoriatic keratinocytes by lithium. Archives of Dermatological Research, 1996, 288, 173-178.	1.1	37
67	TYPE-1 PLASMINOGEN ACTIVATOR INHIBITOR IN HUMAN RENAL CELL CARCINOMA. , 1996, 179, 95-99.		11
68	Lithium and psoriasis: cytokine modulation of cultured lymphocytes and psoriatic keratinocytes by lithium. Archives of Dermatological Research, 1996, 288, 173-178.	1.1	3
69	Ras Gene Mutation: A Rare Event in Nonmetastatic Primary Malignant Melanoma. Journal of Investigative Dermatology, 1995, 104, 868-871.	0.3	33
70	Tyrosine Phosphorylation in Psoriatic T Cells Is Modulated by Drugs That Induce or Improve Psoriasis. Dermatology, 1995, 191, 217-225.	0.9	20
71	Neuroendocrine neoplasms of the lung are not associated with point mutations at codon 12 of the Ki-ras gene. Vigiliae Christianae, 1993, 63, 325-329.	0.1	17
72	Macrophages in normal human bone marrow and in chronic myeloproliferative disorders: An immunohistochemical and morphometric study by a new monoclonal antibody (PG-M1) on trephine biopsies. Virchows Archiv A, Pathological Anatomy and Histopathology, 1992, 421, 33-39.	1.4	49

#	Article	IF	Citations
73	Expression of Stromelysin 3 in the Stromal Elements of Human Basal Cell Carcinoma. Diagnostic Molecular Pathology, 1992, 1, 200-205.	2.1	28
74	Megakaryocyte precursors (pro-and megakaryoblasts) in bone marrow tissue from patients with reactive thrombocytosis, polycythemia vera and primary (essential) thrombocythemia. Vigiliae Christianae, 1989, 58, 295-302.	0.1	14